949 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Roxbury Financial LLC

Roxbury Financial LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 949 shares of the biopharmaceutical company’s stock, valued at approximately $88,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Roman Butler Fullerton & Co. acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $298,000. AustralianSuper Pty Ltd boosted its stake in Gilead Sciences by 0.5% in the fourth quarter. AustralianSuper Pty Ltd now owns 1,138,269 shares of the biopharmaceutical company’s stock valued at $105,142,000 after acquiring an additional 5,989 shares during the period. Asset Planning Inc acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $76,000. Banque Pictet & Cie SA boosted its stake in Gilead Sciences by 838.6% in the fourth quarter. Banque Pictet & Cie SA now owns 51,621 shares of the biopharmaceutical company’s stock valued at $4,768,000 after acquiring an additional 46,121 shares during the period. Finally, White Pine Capital LLC acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $224,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Oppenheimer lifted their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Royal Bank of Canada lifted their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday. Citigroup began coverage on Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 price target on the stock. Finally, Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Eleven equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $101.33.

Gilead Sciences Trading Down 1.8 %

NASDAQ GILD opened at $104.08 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $106.69. The firm’s 50 day moving average price is $93.87 and its two-hundred day moving average price is $87.55. The stock has a market cap of $129.71 billion, a price-to-earnings ratio of 1,156.44, a PEG ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Equities analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 3.04%. Gilead Sciences’s payout ratio is currently 3,422.22%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 137,676 shares of the business’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the completion of the transaction, the chief financial officer now owns 171,223 shares of the company’s stock, valued at $17,502,415.06. The trade was a 44.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 710,500 shares of company stock valued at $67,684,956 in the last quarter. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.